Document Detail


Recent advances in the understanding of the pathophysiology and treatment of hyperprolactinemia.
MedLine Citation:
PMID:  8329652     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Hyperprolactinemia is frequently diagnosed in patients with infertility and menstrual cycle irregularities. Control of prolactin secretion is complex and involves inhibition by dopamine and possibly endothelins, as well as stimulation by serotoninergic and opioidergic pathways, gonadotropin-releasing hormone, and possibly galanin. Some patients with hyperprolactinemia have underlying functional disorders, but by using magnetic resonance imaging, a microprolactinoma can be found in most. Prolactin circulates in a low-bioactivity glycosylated and a nonglycosylated form, and an antibody-bound form is found in a few hyperprolactinemic patients who are relatively asymptomatic. The majority of patients, particularly those with macroprolactinomas, will benefit from treatment with bromocriptine. Available alternatives for intolerant patients include vaginal administration of bromocriptine and pergolide mesylate. Other compounds, monthly injectable and slow-release forms of bromocriptine, quinagolide and carbegoline, are not yet available in the United States. Withdrawal of treatment during pregnancy is still recommended, with a low risk of tumor enlargement, and the need for life-long treatment is now being reconsidered.
Authors:
V Sarapura; W D Schlaff
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current opinion in obstetrics & gynecology     Volume:  5     ISSN:  1040-872X     ISO Abbreviation:  Curr. Opin. Obstet. Gynecol.     Publication Date:  1993 Jun 
Date Detail:
Created Date:  1993-08-19     Completed Date:  1993-08-19     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9007264     Medline TA:  Curr Opin Obstet Gynecol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  360-7     Citation Subset:  IM    
Affiliation:
University of Colorado Health Sciences Center, Denver.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Bromocriptine / therapeutic use
Female
Humans
Hyperprolactinemia / blood,  diagnosis,  drug therapy*,  physiopathology*
Magnetic Resonance Imaging
Pergolide / therapeutic use
Prolactin / biosynthesis,  blood
Receptors, Dopamine D2 / drug effects
Signal Transduction
Treatment Outcome
Chemical
Reg. No./Substance:
0/Receptors, Dopamine D2; 25614-03-3/Bromocriptine; 66104-22-1/Pergolide; 9002-62-4/Prolactin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The potential roles of intraovarian peptides in normal and abnormal mechanisms of reproductive physi...
Next Document:  New advances in the treatment of infertility in women with ovarian failure.